ArticleRenal failure2025
Serum steroid metabolome pattern is associated with the response to prednisolone therapy of male patients with IgA nephropathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy (IgAN) is characterized by the deposition of galactose-deficient IgA1 (Gd-IgA1)-containing immune complexes into kidney mesangium leading to glomerular inflammation and injury. In patients with active IgAN non-responding to renin-angiotensin system blocking drugs (RASBs), corticosteroids (CSs) are recommended. Although CSs reduce significantly serum levels of Gd-IgA1, IgA-containing immune complexes, and proteinuria, their clinical effect in IgAN is variable. Because IgAN patients exhibit abnormal serum concentration of several endogenous steroid metabolites, some of which exhibit immuno-protective/regulating functions, we analyzed serum metabolites which could predict clinical response to CS therapy. This prospective study was performed in 18 male IgAN patients to identify potential biomarkers for personalized CS therapy. Using LC-MS set of 85 steroid metabolites was tested in the sera of IgAN patients before CS therapy initiation to identify those with statistically different level in patients clinically responding and not-responding to CS therapy. Responders were those subjects whose proteinuria decrease below 1 g/day after 6-12 months of CS therapy. Statistical analysis revealed significant and clinically relevant differences in the steroid profile between responders and non-responders. The key and consistent finding across the entire analysis is that non-responder status is associated with globally higher level of almost all analyzed steroids. The response of IgAN patients to CS therapy could be predicted by measuring the serum levels of selected steroid metabolites to receive steroid profile. Observation needs to be confirmed in large cohorts of various ethnic origin to be applicable for routine clinical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.